Amundi’s Intra-Cellular Therapies Inc. ITCI Stock Holding History

Amundi’s Portfolio ITCI Stock Details ITCI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q2	–	Sell	-561,266	Closed	-$74M	–	2240
2025 Q1	$74M	Buy	561,266 +558,537	+20,467%	+$69.6M	0.03%	470
2024 Q4	$225K	Sell	2,729 -206	-7%	-$16.9K	﹤0.01%	1711
2024 Q3	$212K	Buy	+2,935	New	+$221K	﹤0.01%	1642

Other funds holding ITCI

DekaBank Deutsche Girozentrale Frankfurt, Germany $60.6B AUM 23.27% 1-Year Est. Return

Osaic Holdings Scottsdale, Arizona $68.3B AUM 20.5% 1-Year Est. Return

KIM

Kestra Investment Management Austin, Texas $5.8B AUM 14.71% 1-Year Est. Return

HNB

Huntington National Bank Columbus, Ohio $18.1B AUM 24.69% 1-Year Est. Return

Amundi's ITCI Position: Q2 2025 in Review

Amundi sold out of Intra-Cellular Therapies Inc. (ITCI) in Q2 2025, closing a stake of 561,266 shares — an estimated $74M sold.

Amundi first reported a position in ITCI in Q3 2024 and held it in 3 quarters. The position peaked at $74M in Q1 2025. 4 funds tracked by Wall St. Rank hold ITCI as of Q2 2025.

Amundi reported no remaining Intra-Cellular Therapies Inc. position as of Q2 2025 after selling out during the quarter.
Amundi sold 561,266 Intra-Cellular Therapies Inc. shares in Q2 2025, an estimated $74M.
Amundi first reported a position in Intra-Cellular Therapies Inc. in Q3 2024 and held it in 3 quarters.
Amundi's Intra-Cellular Therapies Inc. position peaked at $74M in Q1 2025.
4 funds tracked by Wall St. Rank held Intra-Cellular Therapies Inc. as of Q2 2025.

Based on Amundi's 13F filing for Q2 2025, filed 13 Aug 2025.